We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$7.2M
Cap. Flow
-$2.16M
Cap. Flow %
-0.37%
Top 10 Hldgs %
36.51%
Holding
220
New
75
Increased
41
Reduced
27
Closed
76

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.57M
2
UTHR icon
United Therapeutics
UTHR
+$8.62M
3
INCY icon
Incyte
INCY
+$7.79M
4
COGT icon
Cogent Biosciences
COGT
+$7.05M
5
VKTX icon
Viking Therapeutics
VKTX
+$6.05M

Top Sells

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.95M
2
TERN
Terns Pharmaceuticals
TERN
+$6.74M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.21M
4
BIOA
BioAge Labs
BIOA
+$4.07M
5
CORT icon
Corcept Therapeutics
CORT
+$3.27M

Sector Composition

1 Healthcare 38.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
76
CALL
EyePoint Inc
EYPT
$1.09B
$1.37M 0.23%
+106,300
New +$1.59M
KPTI icon
77
CALL
Karyopharm Therapeutics
KPTI
$213M
$1.34M 0.23%
+241,300
New +$1.84M
SLS icon
78
CALL
SELLAS Life Sciences
SLS
$2.31B
$1.27M 0.22%
300,000
-124,900
-29% -$559K
OLMA icon
79
CALL
Olema Pharmaceuticals
OLMA
$967M
$1.25M 0.21%
84,000
-12,100
-13% -$269K
CRMD icon
80
PUT
CorMedix
CRMD
$650M
$1.14M 0.19%
167,500
+8,500
+5% +$62.8K
CRBP icon
81
CALL
Corbus Pharmaceuticals
CRBP
$163M
$1.08M 0.18%
+115,300
New +$971K
IOVA icon
82
CALL
Iovance Biotherapeutics
IOVA
$2.08B
$1.05M 0.18%
+300,000
New +$960K
BIOA
83
BioAge Labs
BIOA
$985M
$1.05M 0.18%
60,000
-211,164
-78% -$4.07M
INO icon
84
Inovio Pharmaceuticals
INO
$92.1M
$979K 0.17%
562,665
+28,983
+5% +$47.7K
AYTU icon
85
AYTU BioPharma
AYTU
$23.2M
$964K 0.16%
353,077
+47,289
+15% +$121K
EQ icon
86
Equillium
EQ
$158M
$868K 0.15%
433,844
+86,451
+25% +$142K
DNTH icon
87
Dianthus Therapeutics
DNTH
$5.21B
$839K 0.14%
+10,000
New +$579K
PHVS icon
88
Pharvaris
PHVS
$2.35B
$828K 0.14%
+29,321
New +$783K
ENTA icon
89
Enanta Pharmaceuticals
ENTA
$384M
$820K 0.14%
64,952
-186
-0.3% -$2.49K
IBRX icon
90
PUT
ImmunityBio
IBRX
$7.8B
$815K 0.14%
+106,300
New +$728K
VIR icon
91
CALL
Vir Biotechnology
VIR
$1.59B
$796K 0.14%
88,800
-400
-0.4% -$3.19K
REPL icon
92
Replimune Group
REPL
$799M
$770K 0.13%
100,660
-130,337
-56% -$996K
XERS icon
93
Xeris Biopharma Holdings
XERS
$1.5B
$770K 0.13%
132,746
-37,822
-22% -$251K
LRMR icon
94
Larimar Therapeutics
LRMR
$381M
$750K 0.13%
+166,637
New +$666K
ANNX icon
95
Annexon
ANNX
$965M
$736K 0.13%
132,916
-217,084
-62% -$1.22M
RARE icon
96
Ultragenyx Pharmaceutical
RARE
$2.98B
$736K 0.13%
+35,144
New +$791K
MLYS icon
97
Mineralys Therapeutics
MLYS
$2.39B
$714K 0.12%
26,347
+1,347
+5% +$39.5K
UNCY icon
98
Unicycive Therapeutics
UNCY
$138M
$698K 0.12%
+106,083
New +$695K
ALMS
99
PUT
Alumis Inc
ALMS
$3.47B
$687K 0.12%
+31,200
New +$780K
SPRB
100
Spruce Biosciences
SPRB
$122M
$654K 0.11%
+10,000
New +$690K
2 3
4
5 6

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Diadema Partners held 220 positions worth $588M, up 1.2% from $581M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners's Q1 2026 filing shows 75 new, 41 increased, 27 reduced and 76 closed positions. Its largest new stake was Jazz Pharmaceuticals: 54,755 shares worth $10.4M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier.

  • Diadema Partners's largest Q1 2026 buy was Jazz Pharmaceuticals: 54,755 shares worth $10.4M.
  • Diadema Partners added most to United Therapeutics in Q1 2026, an estimated $8.62M increase.
  • Diadema Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $6.74M.
  • Diadema Partners fully exited Regeneron Pharmaceuticals in Q1 2026, selling an estimated $7.95M.
  • Diadema Partners's ten largest holdings make up 37% of its $588M portfolio in Q1 2026.
  • Diadema Partners opened 75 new positions and closed 76 in Q1 2026.
  • Diadema Partners's portfolio value rose 1.2% quarter-over-quarter to $588M.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.